Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study Group.
Bairey O, Goldschmidt N, Ruchlemer R, Tadmor T, Rahimi-Levene N, Yuklea M, Shvidel L, Berrebi A, Polliack A, Herishanu Y; Israeli Chronic Lymphocytic Leukemia Study Group (ICLLSG). Bairey O, et al. Among authors: polliack a. Eur J Haematol. 2012 Dec;89(6):491-6. doi: 10.1111/ejh.12015. Epub 2012 Oct 26. Eur J Haematol. 2012. PMID: 23033927
Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group.
Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Klepfish A, Ruchlemer R, Berrebi A, Polliack A; Israeli CLL Study Group. Shvidel L, et al. Among authors: polliack a. Eur J Haematol. 2014 Jul;93(1):29-33. doi: 10.1111/ejh.12290. Epub 2014 Mar 12. Eur J Haematol. 2014. PMID: 24547751
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Joffe E, Goldschmidt N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Arad A, Polliack A, Herishanu Y; Israeli CLL Study Group. Joffe E, et al. Among authors: polliack a. Eur J Haematol. 2018 Sep;101(3):399-406. doi: 10.1111/ejh.13129. Epub 2018 Aug 3. Eur J Haematol. 2018. PMID: 29949186
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A. Herishanu Y, et al. Among authors: polliack a. Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12. Hematol Oncol. 2019. PMID: 30756414 Clinical Trial.
A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain.
Tadmor T, Braester A, Najib D, Aviv A, Herishanu Y, Yuklea M, Shvidel L, Rahimi-Levene N, Ruchlemer R, Arad A, Fogl C, Henig C, Barak M, Magal L, Polliack A, Townsend K; Israeli CLL study group. Tadmor T, et al. Among authors: polliack a. Eur J Haematol. 2019 Oct;103(4):335-341. doi: 10.1111/ejh.13288. Epub 2019 Jul 26. Eur J Haematol. 2019. PMID: 31278876
477 results